A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
This study is ongoing, but not recruiting participants.
Sponsor:
Vertex Pharmaceuticals Incorporated
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:
NCT01467479
First received: November 3, 2011
Last updated: October 19, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to treat HIV and HCV coinfected subjects with telaprevir, peg-interferon alfa-2a, and ribavirin to achieve undetectable HCV RNA 12 weeks after the last planned dose of study drug.
Condition | Intervention | Phase |
---|---|---|
Hepatitis C |
Drug: Telaprevir Drug: Ribavirin Biological: peginterferon alfa-2a |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) |
Resource links provided by NLM:
Further study details as provided by Vertex Pharmaceuticals Incorporated:
Primary Outcome Measures:
- Proportion of subjects who achieve undetectable HCV RNA 12 weeks after the last planned dose of study drug (sustained viral response [SVR12]) [ Time Frame: 12 weeks after the last planned dose of study drug ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Proportion of subjects who achieve undetectable HCV RNA 24 weeks after the last planned dose of study drug (SVR24) [ Time Frame: 24 weeks after the last planned dose of study drug ] [ Designated as safety issue: No ]
- Proportion of subjects who achieve undetectable HCV RNA at Week 4 (rapid viral response [RVR]), Week 4 and Week 12 (extended rapid viral response [eRVR]), and planned End of Treatment (EOT) [ Time Frame: up to 48 Weeks ] [ Designated as safety issue: No ]
- Safety as assessed by AEs, clinical laboratory results, HIV RNA assessments, CD4 counts, 12 lead electrocardiograms (ECGs), and vital signs [ Time Frame: up to 52 Weeks ] [ Designated as safety issue: Yes ]
- PK of telaprevir, Peg IFN, RBV, and pre-defined HAART medications [ Time Frame: up to 52 Weeks ] [ Designated as safety issue: No ]
- Amino acid sequence of the HCV NS3•4A protease region [ Time Frame: up to 96 Weeks ] [ Designated as safety issue: No ]
Estimated Enrollment: | 160 |
Study Start Date: | January 2012 |
Estimated Primary Completion Date: | September 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Relapsers and Naives (eRVR+)
Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks followed by Peg-IFN-alfa-2a + RBV for 12 weeks eRVR+: undetectable HCV RNA at Weeks 4 and 12 |
Drug: Telaprevir
1125 mg bid or 1125 mg tid (with efavirenz based regimens)for 12 weeks.
Drug: Ribavirin
800 mg/day for 24 or 48 weeks.
Biological: peginterferon alfa-2a
180 mcg/week for 24 or 48 weeks
|
Experimental: Relapsers and Naives (eRVR-)
Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks eRVR-: detectable HCV RNA at Week 4 or Week 12 |
Drug: Telaprevir
1125 mg bid or 1125 mg tid (with efavirenz based regimens)for 12 weeks.
Drug: Ribavirin
800 mg/day for 24 or 48 weeks.
Biological: peginterferon alfa-2a
180 mcg/week for 24 or 48 weeks
|
Experimental: Null/Partial
All Null/Partial subjects receive Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks
|
Drug: Telaprevir
1125 mg bid or 1125 mg tid (with efavirenz based regimens)for 12 weeks.
Drug: Ribavirin
800 mg/day for 24 or 48 weeks.
Biological: peginterferon alfa-2a
180 mcg/week for 24 or 48 weeks
|
Eligibility
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA >1000 IU/mL
- Population A: HCV Peg IFN/RBV treatment naive (received no prior HCV therapy)or Peg-IFN/RBV prior treatment with relapse
- Population B: Peg-INF/RBV prior null or partial responder
- Subjects must not have achieved SVR24 after at least 1 prior course of Peg IFN/RBV therapy of standard duration
- Subject must have positive HIV antibody at Screening
- Subject must have a diagnosis of HIV-1 infection >6 months before Screening
Subjects should be taking 1 of the following permissible HAART regimens for HIV continuously for 12 weeks prior to screening:
- Atripla® or equivalent components (efavirenz, tenofovir, emtricitabine)
- Efavirenz plus Epzicom® (abacavir, lamivudine) or equivalent components
- Boosted atazanavir (atazanavir with ritonavir) plus Truvada® (tenofovir, emtricitabine) or equivalent components
- Boosted atazanavir plus Epzicom®, or equivalent components
- Raltegravir plus Truvada®, or equivalent components
- Raltegravir plus Epzicom®, or equivalent components
- CD4 counts and HIV-1 RNA meeting acceptable criteria at Screening as specified in the protocol.
- Laboratory values within acceptable ranges at Screening as specified in the protocol
Exclusion Criteria:
- Subjects anticipating a need to switch HAART regimens within 14 weeks after Day 1 or any switches occurring 12 weeks prior to Day 1
- Use of azidothymidine (AZT), didanosine (ddI) or stavudine (d4T) nucleosides
- Contraindications to any planned HAART component as per the respective drug labeling information
- Contraindications to Peg IFN or RBV
- Evidence of hepatic decompensation
- Clinical suspicion of acute hepatitis
- Any other cause of liver disease in addition to hepatitis C
- History of organ transplantation (except cornea and skin)
- Autoimmune-mediated disease
- Participated in any investigational drug study within 90 days before Day 1
- Previous treatment with an HCV protease inhibitor
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01467479
Show 59 Study Locations
Show 59 Study Locations
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Investigators
Study Director: | Medical Monitor | Vertex Pharmaceuticals Incorporated |
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 03, 2013
No publications provided
Responsible Party: | Vertex Pharmaceuticals Incorporated |
ClinicalTrials.gov Identifier: | NCT01467479 History of Changes |
Other Study ID Numbers: | VX11-950-115 |
Study First Received: | November 3, 2011 |
Last Updated: | October 19, 2012 |
Health Authority: | United States: Food and Drug Administration Canada: Health Canada Germany: Federal Institute for Drugs and Medical Devices Spain: Agencia Española de Medicamentos y Productos Sanitarios |
Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome HIV Infections Hepatitis Hepatitis A Hepatitis C Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases Liver Diseases |
Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections Flaviviridae Infections Ribavirin Peginterferon alfa-2a Interferon-alpha Antiviral Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antimetabolites Molecular Mechanisms of Pharmacological Action Immunologic Factors |
ClinicalTrials.gov processed this record on March 03, 2013